Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Affect and self-control outcomes following DLPFC and medial orbitofrontal rTMS in tobacco use disorder: Secondary analyses from a randomized sham-controlled trial.

Brain stimulation·2026

Same author

Lower leg EMG and H-reflex activity during double-leg hopping and landing.

Journal of neurophysiology·2026

Same author

DLPFC rTMS is more effective than sham or orbitofrontal stimulation for smoking cessation and alters frontal brain activity: A double-blind, sham-controlled randomized clinical trial.

Journal of psychiatric research·2026

Same author

A pilot study of dronabinol for the treatment of pain in sickle cell disease.

Pilot and feasibility studies·2025

Same author

Biofeedback Training for 3-Dimensional Finger Force Control to Improve Upper Limb Function Poststroke: An RCT.

Stroke·2025

Same author

Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trial.

The Lancet. Neurology·2025

Search research articles

Related Experiment Video

Updated: Jan 9, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Phase II trials powered to detect tumor subtypes.

John D Roberts¹, Viswanathan Ramakrishnan

¹Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|July 9, 2011

Summary

This study introduces a novel two-stage Phase II clinical trial design for cancer research. This adaptive approach allows for tumor characterization and subtype selection, improving efficiency in identifying effective treatments.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jan 9, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Clinical Trial Design
Biostatistics

Background:

Classical Phase II trial designs necessitate prospective tumor characterization.
Existing adaptive designs often require extensive upfront tumor profiling.

Purpose of the Study:

To propose a novel two-stage Phase II clinical trial design.
To enable tumor characterization and subtype selection after Stage 1.
To offer flexible Stage 2 objectives, including response rate estimation or hypothesis testing for subtypes.

Main Methods:

A two-stage adaptive design is presented.
Stage 1 involves tumor characterization and subtype selection.
Stage 2 focuses on response rate estimation or comparative hypothesis testing.

Main Results:

Stage 1 sample sizes range from 20-100 (usual 50), larger than classical designs (12-30).
Total sample sizes vary from classical Phase II to Phase III scales.
The proposed design is more efficient than prior adaptive designs due to post-Stage 1 subtype selection.

Conclusions:

This design enhances efficiency by allowing tumor subtype selection based on Stage 1 data.
It complements existing Phase II and III designs by fixing treatment and varying tumor subtype.
Offers a flexible framework for optimizing cancer clinical trials.